中国肿瘤化疗相关贫血诊治专家共识（2019年版）  

A consensus on the clinical diagnosis, treatment, and prevention of cancer-and chemotherapy-related anemia in China(2019 edition)

作　　者：无 史艳侠[3] 邢镨元 张俊[6] 沈波[7] 姜文奇[3] 巴一[8] 冯继锋 

机构地区：[1]中国抗癌协会肿瘤支持治疗专业委员会 [2]中国抗癌协会肿瘤临床化疗专业委员会 [3]中山大学肿瘤防治中心 [4]国家癌症中心 [5]中国医学科学院肿瘤医院 [6]上海交通大学医学院附属瑞金医院 [7]江苏省肿瘤医院 [8]天津医科大学肿瘤医院

出　　处：《中国肿瘤临床》2019年第17期869-875,共7页Chinese Journal of Clinical Oncology

摘　　要：肿瘤化疗相关贫血(chemotherapy-related anemia,CRA)为肿瘤患者常见的不良反应,发生率与肿瘤类型、治疗方案和化疗周期等均有关,其发病机制尚未明确。CRA有可能导致化疗药物剂量降低、化疗时间延迟、需要输注红细胞等,从而增加患者的治疗费用、降低化疗效果和患者的生存质量、缩短生存时间。CRA的主要治疗包括输注红细胞、促红细胞生成治疗和补充铁剂等。基于近期文献及临床研究,中国抗癌协会肿瘤临床化疗专业委员会和肿瘤支持治疗专业委员会制订了《中国肿瘤化疗相关贫血诊治专家共识(2019年版)》,旨在为中国肿瘤学医师提供更为合理的诊疗方案,从而帮助患者改善肿瘤化疗相关贫血,提高生存质量。Cancer-and chemotherapy-related anemia(CRA)is a common side effect in patients with tumors,the incidence of which is related to tumor type,treatment regimen,the duration of chemotherapy,etc.The pathogenesis of CRA has not been fully defined.CRA may lead to chemotherapy dose reduction or may even delay chemotherapy.Patients with CRA require red blood cell transfusion,thus increasing the treatment cost,reducing the efficiency of chemotherapy and the patient's quality of life,and shortening the survival time.The main treatments of CRA include red blood cell transfusion,iron supplements,erythropoietin,and so on.Based on recent literature and clinical studies,the expert committee of the China Anti-Cancer Association drew up the consensus on the diagnosis and treatment of anemia related to tumor chemotherapy in China(2019 edition),aiming to provide more reliable diagnosis and treatment plans for Chinese oncologists to help improve CRA and the quality of life in patients with cancer.

关 键 词：中国抗癌协会 专家共识 肿瘤化疗所致贫血 铁剂 促红细胞生成治疗 

分 类 号：R73[医药卫生—肿瘤]